Goldman Sachs Maintains Buy on IDEAYA Biosciences, Raises Price Target to $37
Portfolio Pulse from Benzinga Newsdesk
Goldman Sachs analyst Corinne Jenkins maintains a Buy rating on IDEAYA Biosciences (NASDAQ:IDYA) and raises the price target from $31 to $37.
September 12, 2023 | 12:32 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Goldman Sachs maintains a Buy rating on IDEAYA Biosciences and raises the price target from $31 to $37, which could lead to a positive market reaction.
The raised price target by Goldman Sachs, a reputable financial institution, indicates a positive outlook for IDEAYA Biosciences. This could lead to increased investor confidence and potentially a rise in the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100